Treatment Outcomes and Long-term Survival in Patients with Extensively Drug-resistant Tuberculosis

Kim, Doh Hyung; Kim, Hee Jin; Park, Seung-Kyu; Kong, Suck‐Jun; Kim, Young Sam; Kim, Tae-Hyung; Kim, Min Jung; Lee, Ki Man; Lee, Sung-Soon; Park, Jae Seuk; Koh, Won‐Jung; Lee, Chang‐Hoon; Kim, Ji Yeon; Shim, Tae Sun

doi:10.1164/rccm.200801-132oc

Cited by 155 publications

(151 citation statements)

References 21 publications

Supporting

Mentioning

132

Contrasting

Order By: Relevance

“…This observation agrees with a study conducted in the United States wherein 50% of MDR-TB patients with HIV died (33); most patients these were severely immunosuppressed. The early mortality rate of MDR-TB patients with HIV has also been studied in South Africa and Malaysia (6,34). The high early mortality rate in this study argues for early initiation of second-line TB drugs in MDR-TB patients.…”

Section: Discussionmentioning

confidence: 66%

“…Therapeutic options for XDR-TB are exceedingly limited because second-line drugs are less effective and more toxic and expensive than first-line drugs; by definition, XDR-TB strains are resistant to more potent second-line options. Several new drugs are being evaluated for XDR-TB treatment but none are currently available (23).…”

Section: Discussionmentioning

confidence: 99%

“…According to the WHO (2013), at least one case of XDR-TB was reported in 92 countries at the end of 2012. An estimated 9.8% of all MDR-TB cases develop into XDR-TB (6,7).…”

Section: Introductionmentioning

confidence: 99%

“…Moreover, treatment for patients with MDR-TB strains is more expensive, complicated, and toxic and less effective than treatment for susceptible TB strains and MDR-TB strains are transmittable over long periods of time, even under treatment (8). Primary and acquired drug resistance are common, with the latter caused by inappropriate regimen prescription or patient non-adherence (6).…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Treatment Outcomes of Patients with Multidrug-Resistant Tuberculosis (MDR- TB) Compared with Non-MDR-TB Infections in Peninsular Malaysia

Elmi

Hasan

Abdullah

et al. 2016

MJMS

View full text Add to dashboard Cite

Background: Treating patients with multidrug-resistant tuberculosis (MDR-TB) strains is more complicated, complex, toxic, expensive, than treating patients with susceptible TB strains. This study aims to compare the treatment outcomes and potential factors associated between patients with MDR-TB and non MDR TB infections in peninsular Malaysia.Methods: This study was a retrospective cohort study. Data were collected from the medical records of all registered MDR-TB patients and Non-MDR-TB patients at five TB hospitals in peninsular Malaysia from January 2010 to January 2014.Results: A total of 314 subjects were studied, including 105 MDR-TB cases and 209 non-MDR-TB. After TB treatment, 24.8% of the MDR-TB patients and 17.7% of non MDR TB relapsed; 17.1% of the MDR-TB patients and 16.3% of non MDR TB defaulted from TB treatment. A significant difference seen in treatment success rate 17.1% for MDR-TB; 63.1% for non MDR TB (P < 0.001)). Mortality rate were 8.9% for MDR-TB; 13.2% for non MDR TB. Multivariable analysis showed the potential factors associated with poor treatment outcomes were presence of HIV infection (AOR, 1.09; 95%CI: 1.05, 1.75; P = 0.001) and previous TB treatment (AOR, 4.87; 95%CI: 2.84, 8.38; P = 0.001).Conclusion: This study revealed that the treatment success rate in patients with non MDR TB infection was higher than MDR-TB. Unsuccessful treatment was seen in MDR-TB associated with potential factors such as history of TB treatment, and presence of HIV infection.

show abstract

Section: Discussionmentioning

confidence: 66%

Section: Discussionmentioning

confidence: 99%

“…According to the WHO (2013), at least one case of XDR-TB was reported in 92 countries at the end of 2012. An estimated 9.8% of all MDR-TB cases develop into XDR-TB (6,7).…”

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Treatment Outcomes of Patients with Multidrug-Resistant Tuberculosis (MDR- TB) Compared with Non-MDR-TB Infections in Peninsular Malaysia

Elmi

Hasan

Abdullah

et al. 2016

MJMS

View full text Add to dashboard Cite

show abstract

“…Thus, it seems very clear that fluoroquinolones are the key in the outcome of MDR-TB and even XDR-TB treatment. Regarding the role of the secondline injectable drugs in the favourable outcome of the MDR-TB patients, the situation is little controversial [6,9,24], although some recent studies suggest that their role is key [25,26].…”

Section: Discussionmentioning

confidence: 99%

Linezolid: an effective, safe and cheap drug for patients failing multidrug-resistant tuberculosis treatment in India

Singla¹,

Caminero²,

Jaiswal³

et al. 2011

Eur Respir J

View full text Add to dashboard Cite

Linezolid is identified as an effective drug with which to treat patients failing multidrug-resistant (MDR)-tuberculosis (TB) treatment. However, cost and safety are the concerns. In India, the average price of a 600-mg pill of linezolid is less than one US dollar, much cheaper than most of the third-line drugs.A prospective study of 29 MDR-TB treatment failure patients (16 with laboratory-proven extensively drug-resistant (XDR)-TB and the remaining 13 with MDR-TB with resistance to any quinolone but sensitive to injectables) was carried out in Delhi, India. All patients received daily unsupervised therapy with linezolid, one injectable agent, one fluoroquinolone and two or more other drugs.Patients received a median of six anti-mycobacterial agents. Besides linezolid, capreomycin, moxifloxacin, levofloxacin and amoxycillin-clavulanic acid were used in 41.4%, 58.6%, 41.4%, and 79.3% of patients. Out of a total of 29 patients, 89.7% patients achieved sputum smear and culture conversion; 72.4% showed interim favourable outcome; 10.3% died, 6.8% failed and 10.3% patients defaulted. Linezolid had to be stopped in three (10.3%) patients due to adverse reactions. The outcome of treatment of 16 XDR-TB patients was comparable to the other 13 MDR-TB patients.Linezolid is an effective, cheap and relatively safe drug for patients failing MDR-TB treatment, including those with confirmed XDR-TB.

show abstract

Anti‐tuberculosis Agents

Zhang

2019

Bacterial Resistance to Antibiotics – From Molecules to Man

View full text Add to dashboard Cite

Treatment Outcomes and Long-term Survival in Patients with Extensively Drug-resistant Tuberculosis

Cited by 155 publications

References 21 publications

Treatment Outcomes of Patients with Multidrug-Resistant Tuberculosis (MDR- TB) Compared with Non-MDR-TB Infections in Peninsular Malaysia

Treatment Outcomes of Patients with Multidrug-Resistant Tuberculosis (MDR- TB) Compared with Non-MDR-TB Infections in Peninsular Malaysia

Linezolid: an effective, safe and cheap drug for patients failing multidrug-resistant tuberculosis treatment in India

Anti‐tuberculosis Agents

Contact Info

Product

Resources

About